vs
Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and Opera Ltd (OPRA). Click either name above to swap in a different company.
BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($156.4M vs $142.7M, roughly 1.1× Opera Ltd).
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Opera is a multinational technology corporation headquartered in Oslo, Norway, with additional offices in Europe, China, and Africa. Opera offers a range of products and services that include PC and mobile web browsers, GameMaker and gaming portals, the Opera News content recommendation products, the Opera Ads platform, and a number of Web3 and e-commerce products and services. The company's total user base is 296 million monthly active users.
BCRX vs OPRA — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $156.4M | $142.7M |
| Net Profit | — | $18.3M |
| Gross Margin | — | — |
| Operating Margin | 13.6% | 14.8% |
| Net Margin | — | 12.8% |
| Revenue YoY | 7.5% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.00 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | — | ||
| Q3 25 | $159.4M | — | ||
| Q2 25 | $163.4M | — | ||
| Q1 25 | $145.5M | $142.7M | ||
| Q4 24 | $131.5M | — | ||
| Q3 24 | $117.1M | — | ||
| Q2 24 | $109.3M | $211.6M |
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | — | ||
| Q3 25 | $12.9M | — | ||
| Q2 25 | $5.1M | — | ||
| Q1 25 | $32.0K | $18.3M | ||
| Q4 24 | $-26.8M | — | ||
| Q3 24 | $-14.0M | — | ||
| Q2 24 | $-12.7M | $34.1M |
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | — | ||
| Q3 25 | 98.6% | — | ||
| Q2 25 | 98.3% | — | ||
| Q1 25 | 96.9% | — | ||
| Q4 24 | 95.4% | — | ||
| Q3 24 | 97.3% | — | ||
| Q2 24 | 98.4% | — |
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | — | ||
| Q3 25 | 18.6% | — | ||
| Q2 25 | 18.2% | — | ||
| Q1 25 | 14.6% | 14.8% | ||
| Q4 24 | -3.4% | — | ||
| Q3 24 | 6.6% | — | ||
| Q2 24 | 8.0% | 19.6% |
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | — | ||
| Q3 25 | 8.1% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 0.0% | 12.8% | ||
| Q4 24 | -20.4% | — | ||
| Q3 24 | -12.0% | — | ||
| Q2 24 | -11.6% | 16.1% |
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $0.02 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | $-0.07 | — | ||
| Q2 24 | $-0.06 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | — |
| Total Assets | $465.1M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | — | ||
| Q3 25 | $212.9M | — | ||
| Q2 25 | $260.0M | — | ||
| Q1 25 | $295.1M | — | ||
| Q4 24 | $320.9M | — | ||
| Q3 24 | $96.8M | — | ||
| Q2 24 | $78.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | — | ||
| Q3 25 | $-387.9M | — | ||
| Q2 25 | $-421.6M | — | ||
| Q1 25 | $-451.9M | — | ||
| Q4 24 | $-475.9M | — | ||
| Q3 24 | $-468.6M | — | ||
| Q2 24 | $-475.6M | — |
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | — | ||
| Q3 25 | $446.4M | — | ||
| Q2 25 | $457.2M | — | ||
| Q1 25 | $480.0M | — | ||
| Q4 24 | $490.4M | — | ||
| Q3 24 | $491.3M | — | ||
| Q2 24 | $472.4M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
OPRA
Segment breakdown not available.
